The highest JAK2 V617F percentage was recorded in the patient with PMF, which is in line with previous data (unpublished). A highly significant correlation was found between levels of JAK2 V617F percentages in PB and BM, (Spearman's r ¼ 0.76; P ¼ 0.007) (Figure 1 ). Furthermore, in the seven patients from whom both a BM biopsy and a representative BM aspirate were available, the JAK2 V617F proportion determined in the two different BM samples was equivalent (Spearman's r ¼ 0.96; P ¼ 0.0005). The amount of extracted DNA, reflected by the cycle threshold (C t ) value, was higher in the BM aspirates compared to the BM biopsies (data not shown). This finding might be explained by degradation of DNA caused by the formic acid decalcification procedure. It is evident that some patients, in particular with ET, have rather small JAK2 V617F allele burdens below 10%. 4, 7 None of the patients in the present study had such low levels of JAK2 V617F alleles. However, it is interesting that patient no. 2 with 21% JAK2 V617F alleles in PB is the only patient in this series with a significantly larger JAK2 mutant burden in BM. This may be an indication that patients with low levels of detectable JAK2 V617F allele burden in PB may have harbored a significantly larger mutant burden in BM. Future studies of 'low-burden' JAK2 V617F-positive patients could elucidate a theoretical model of increasing propensity of the mutant cells to egress from the BM as the mutant burden in BM increases, as it is observed with CD34-positive cells in IMF. In this study, we have demonstrated that the levels of the JAK2 V617F alleles in PB and BM is equivalent, at least in patients with a mutant clone in PB accounting for more than 30%. The quantification of the JAK2 V617F mutant clone in PB unfractionized WBCs is an exact and reliable determinant of disease burden at diagnosis. As the clonal involvement of various mature hematopoietic cells is very heterogenous and varies between patients, and a separation of, for example, granulocytes is sometimes difficult because of in vivo and in vitro aggregation of monocytes, granulocytes and platelets, 8 the use of unfractionized WBC as DNA source seems rational. Hereby the timeto-time uncertainty and potential bias from an unsuccessful separation procedure are eliminated. A prospective trial elucidating the dynamics of the JAK2 V617F clone with serial measurements of the JAK2 V617F allele burden in both PB and BM during ongoing cytoreductive therapy with, for example, hydroxyurea, interferon-a or a future JAK2 inhibitor is warranted. Studies of cell lineage involvement and of cell origin in acute myeloid leukaemia with normal karyotype (AML-NK) have traditionally been hampered by the lack of clonality markers. Recently, we identified NPM1 mutations as the most common genetic alteration occurring in AML-NK (50-60% of cases).
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NPM1 mutations represent an ideal genetic lesion for tracking cell lineage involvement in AML, as they are usually expressed in all leukaemic cells 1 and are very stable. 2 More importantly, NPM1 mutations generate NPM mutated proteins which are aberrantly expressed in the cytoplasm of leukaemic cells. 3 Thus, NPM cytoplasmic positivity (NPMc þ ) represents a unique tool for studying by immunohistochemistry cell lineage involvement 4 in fixed paraffin-embedded bone marrow samples from NPMc þ AML patients.
Combining immunohistochemistry with analysis of NPM1 mutations on laser-microdissected haemopoietic cells, we found involvement of two or more myeloid lineages in a large proportion of NPMc þ AML. 4 However, whether lymphoid lineages are also involved in NPMc þ AML still remains an open question. Immunohistochemical analysis of reactive lymphoid nodules in bone marrow biopsies from three NPMc þ AML patients did not reveal aberrant cytoplasmic dislocation of NPM, 4 suggesting that lymphoid cells are not targeted by NPM1 mutations. However, reactive lymphoid nodules may not be representative of the B-and T-cell populations resident in the bone marrow or circulating in the peripheral blood of NPMc þ AML patients. Moreover, the data were obtained only in three patients, and therefore, it cannot be excluded that lymphoid cells may be involved in a proportion of NPMc þ AML cases. For example, it is known that certain myeloid-associated mutations (such as JAK2V617) can be detected in lymphoid cells of only a percentage of idiopathic myelofibrosis and polycythemia vera 5 cases. Thus, the possibility that lymphoid cells derive from the neoplastic clone in some cases of NPMc þ AML is not yet fully clarified.
The goals of the present study were to further expand the study of lymphoid cells in a larger number of NPMc þ AML cases and to clarify definitively whether B and T cells from NPMc þ AML patients belong or not to the leukaemic clone. Owing to their low number in AML samples, detection of NPM1 mutations at DNA level on purified or microdissected lymphoid cells is difficult to perform. To overcome this problem, we used anti-NPM antibodies to detect NPM leukaemic mutant proteins in lymphoid cells in B5-fixed/EDTA decalcified paraffinembedded bone marrow biopsies from 20 NPMc þ AML patients (complete details are given in the Supplementary Materials). In all cases, the bone marrow was massively infiltrated by AML cells (Figure 1 Since NPM1 mutations can be predicted through aberrant cytoplasmic expression of NPM1, we investigated the subcellular expression of NPM in B and T cells and compared it with that of neighbouring NPMc þ AML cells. For this purpose, paraffin sections were double stained for CD20/NPM and CD3/ NPM, using a sequential double immunoenzymatic procedure Letters to the Editor that identifies the first antigen (CD20 or CD3) by immunoperoxidase and the second antigen (NPM) by the alkaline phosphatase anti-alkaline phosphatase (APAAP) immunostaining technique. When, in the double immunoenzymatic procedure, NPM was revealed using the mouse monoclonal anti-NPM antibodies (clone 376, which recognizes both wild-type and mutated NPM proteins 4 ), B and T cells showed blue positivity for NPM restricted to the nucleus (the expected staining pattern of wild-type NPM) and a membrane/cytoplasmic-restricted brown positivity for CD20 (B cells) (not shown) or CD3 (T cells) (Supplementary Figure B) . For T cells, these findings were also confirmed by double immunofluorescence labelling ( Figure 2b) ; double immunofluorescence staining for CD20 and NPM was difficult to interpret owing to the low intensity of the signal. Absence of aberrant cytoplasmic expression of NPM in B and T cells strongly suggest that they do not harbour NPM1 mutations. However, since the monoclonal anti-NPM antibody recognizes both the wild-type and NPM-mutated proteins, 4 it cannot be excluded that in lymphoid cells the NPM nuclear positivity may have been at least in part contributed by the NPM mutants. To provide conclusive evidence that B and T cells in these cases truly lack expression of NPM mutants, we used for double staining polyclonal antibodies that recognize specifically the mutated but not the wild-type NPM proteins. Notably, B and T cells showed membrane/cytoplasmic-restricted brown positivity for CD20 (B cells) or CD3 (T cells) but complete (nuclear and cytoplasmic) negativity for the NPM mutants ( Figure 1 , bottom right; Figure 2a, right) . The staining pattern of B and T cells in NPMc þ AML was not influenced by the type of NPM1 mutations, the extent of myeloid cell lineage involvement (single vs more) and the presence/absence of a concomitant FLT3-ITD mutation. These findings provide strong evidence that bone marrow B and T cells in NPMc þ AML do not belong to the leukaemic clone.
To confirm these data at peripheral blood level, we also searched for NPM mutated proteins in circulating B and T lymphocytes from NPMc þ AML patients. Since immunohistochemistry is only suitable for detecting NPM in paraffinembedded material, analysis of peripheral blood B and T lymphocytes was carried out by Western blot with specific anti-NPM mutant antibodies (complete details are given in the Supplementary Materials). T cells were isolated (470% purity at FACS analysis) from peripheral blood mononuclear cells of seven NPMc þ AML patients using the E-rosetting technique, according to standard procedure. B cells were isolated using an immunomagnetic bead technique according to the manufacturer's protocol (Miltenyi Biotec, Bergish Gladbach, Germany).
Sufficient number of purified B cells (90% purity) for Western blot studies was obtained only in two cases of NPMc þ AML. Western blot analysis revealed negativity of all lymphoid populations (either B or T cells) for NPM mutant protein using anti-NPM mutant specific antibodies (Figure 3 ). Clear detection of NPM wild-type protein with an anti-NPM wild-type specific antibody (Invitrogen, Carlsbad, CA, USA) confirmed the quality of the protein extract and, in particular, the expression levels of NPM protein in the sample analysed. Leukaemic cells from the corresponding NPMc þ AML patient were used as a positive control for NPM mutant protein expression (Figure 3 ). These findings demonstrate at biochemical level that peripheral blood B and T cells do not carry NPM leukaemic mutant proteins, further supporting the results of immunohistochemistry in the bone marrow.
The consistent absence of NPM leukaemic mutants in B and T cells of NPMc þ AML suggests that NPM1 mutations may not be prone to target lymphoid cells in general. To address this issue, we stained with the anti-NPM monoclonal antibody (clone 376) paraffin-embedded samples from 723 pathological samples representative of all lymphoid-derived human neoplasms. All cases showed the nucleus-restricted NPM positivity, which is predictive of an NPM1 gene in germline configuration 3 (see Table 1 ). These findings further support the view that NPM1 mutations are a myeloid-specific genetic alteration.
Our results raise important questions concerning the cell of origin of NPMc þ AML. The finding that, despite the frequent involvement of two or more myeloid cell lineages 4 , mature B and T cells are not targeted by NPM1 mutations strongly suggest that the mutation may occur at least in a common myeloid progenitor. However, NPMc þ AML displays a unique gene expression profiling (that is up-regulation of most HOX genes 6 ) which is more characteristic of an upstream haemopoietic stem cell. Thus, another possibility is that the NPM1 mutations might have arisen in the haemopoietic stem cell compartment and then passed onto cells in the committed myeloid precursor fraction, while being lost in the lymphoid lineage. This selective loss could be owing to the fact that the mutation may not confer a selective advantage during lymphoid growth and differentiation. Alternatively, NPM1 mutations may improve a myeloid lineage choice upon common lymphoid progenitors, mimicking the effect of enforced granulocyte/macrophage colony-stimulating factors, 7 or they may even bias differentiation of common lymphoid progenitors to the myeloid lineage via the so-called 'lympho-myeloid progenitors'. 8 Analysis to ascertain whether NPM1 mutations may be present in lympho-myeloid progenitors from NPMc þ AML and are subsequently lost in mature T lymphocytes will require the use of the fetal thymus organ culture assay. 5 Introduction of leukaemia-associated NPM1 mutations into common myeloid and lymphoid progenitors from healthy donors may also help to answer the yet unsolved questions on the cell of origin of NPMc þ AML. Letters to the Editor
